2000.09 - 2004.07  Undergraduate Student in Chemistry, Chemistry College, Jilin University, Jilin Province, China

2004.09 - 2007.07  Joint training Master student in Radiopharmaceuticals, China Institute of Atomic Energy and Peking University, China 　　

2008.09 - 2011.77  Ph.D. in Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, China 　　

2007.10 - 2008.09  Visiting Scholar, Radiochemistry Laboratory, School of Health Sciences, Purdue University, Indiana, USA. Mentor: Prof. Shuang Liu

2010.06 - 2011.01 Research Fellow, Molecular Imaging and Nanomedicine Laboratory, University of Toronto & University Health Network, To ronto, Canada. Mentor: Prof. Gang Zheng

2011.08 - 2014.07  Assistant Professor, Medical and Health Analytical Center & Medical Isotopes Research Center, Peking University, Beijing 100191, China

2014.07 -                Associate Professor, Interdisciplinary Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

2011  Outstanding Graduate Award, Peking University

2011  The Promising Academic Research Talent Award, Peking University(HSC)

2011  Top Prize University Scholarship (top 5%)

2010  Scholarship Award for Excellent Doctoral Student granted by Ministry of Education (￥30,000/year)

2010  Academic Innovation Award, Peking University

2010  Merit Student Award, Peking University

2009  International Travel Award of 18th International Symposium on Radiopharmaceutical Sciences, International Atomic Energy Agency (IAEA)

2009  Academic Innovation Award, Peking University

2016  Gold Medal of the National Science and Technology Workers Innovation and Entrepreneurship Competition of the 18th China Association for Science and Technology Annual Conference

Molecular Imaging, Tumor Targeted Radiotherapy, Translational Nuclear Medicine.

Source: National Natural Science Foundation (General Program)

Title: A Novel Molecular Probe for Imaging Diagnosis and Therapeutic Evaluation of HER2-Positive Tumors

Role: Principal Investigator

Period Covered: 01/2020 to 12/2023

Source: National Natural Science Foundation (General Program) Source: Beijing Natural Science Foundation (General Program)

Title: A Novel Molecular Probe for PET Imaging of Highly Metastatic Tumor Novel

Role: Principal Investigator

Period Covered: 01/2016 to 12/2019

Source: Beijing Natural Science Foundation (General Program)

Title: A Novel Molecular Probe Targeting Tumor Integrin αvβ3 Expression

Role: Principal Investigator

Period Covered: 01/2014 to 12/2016

Source: National Natural Science Foundation Youth Fund

Title: Porphyrin-Based Multifunctional Molecular Probe Targeting Tumor Integrin αvβ3 Expression

Role: Principal Investigator

Period Covered: 01/2012 to 12/2015

1. Zeng X^#, Sun J^#, Li S^#, Shi J^#, Gao H, Leong W, Wu Y, Li M, Liu C, Li P, Kong J, Wu Y*, Nie G*, Fu Y*, and Zhang G*. Blood-triggered generation of platinum nanoparticle functions as an anti-cancer agent. Nat Commun. 2020;11(1):567. doi: 10.1038/s41467-019-14131-z.

2. Gao H^#, Wu Y^#, Shi J^#, Zhang X, Liu T, Hu B, Jia B, Wan Y, Liu Z, and Wang F*. Nuclear Imaging-Guided PD-L1 Blockade Therapy Increases Effectiveness of Cancer Immunotherapy. J Immunother Cancer 2020;0:e001156.

3. Luo Q, Yang G, Gao H, Wang Y, Luo C, Ma X, Gao Y, Li X, Zhao H, Jia B, Shi J* and Wang F*, An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake, Bioconjugate Chem., 2020, 31(5), 1510-1521.

4. Du S, Luo C, Yang G, Gao H, Wang Y, Li X, Zhao H, Luo Q, Ma X, Shi J* and Wang F*. Developing PEGylated Reversed D?Peptide as a Novel HER2-Targeted SPECT Imaging Probe for Breast Cancer Detection. Bioconjugate Chem. 2020, 31, 1971-1980.

5. Gao H, Luo C, Yang G, Du S, Li X, Zhao H, Shi J*, Wang F*. Improved in Vivo Targeting Capability and Pharmacokinetics of (99m)Tc-Labeled isoDGR by Dimerization and Albumin-Binding for Glioma Imaging. Bioconjugate chemistry 2019, 30, 2038-2048.

6. Zhao H, Gao H, Zhai L, Liu X, Jia B, Shi J*, Wang F*. (99m)Tc-HisoDGR as a Potential SPECT Probe for Orthotopic Glioma Detection via Targeting of Integrin α5β1. Bioconjug Chem. 2016 May 18;27(5):1259-66.

7. Shi J, Wang F, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophys Rep. 2016;2(1):1-20. Review.

8. Jing L^#, Shi J^#, Fan D, Li Y, Liu R, Dai Z*, Wang F*, Tian J*. (177)Lu-Labeled Cerasomes Encapsulating Indocyanine Green for Cancer Theranostics. ACS Appl Mater Interfaces. 2015 Oct 7;7(39):22095-105.

9. Fan D, Zhang X, Zhong L, Liu X, Sun Y, Zhao H, Jia B, Liu Z, Zhu Z, Shi J*, Wang F*. (68)Ga-Labeled 3PRGD₂ for Dual PET and Cerenkov Luminescence Imaging of Orthotopic Human Glioblastoma. Bioconjug Chem. 2015 Jun 17;26(6):1054-60.

10. Shi J, Fan D, Dong C, Liu H, Jia B, Zhao H, Jin X, Liu Z, Li F, Wang F. Anti-tumor effect of integrin targeted ¹⁷⁷Lu-3PRGD₂ and combined therapy with endostar. Theranostics. 2014, 4(3):256-66.

11. Shi J^#, Jin Z^#, Liu X, Fan D, Sun Y, Zhao H, Zhu Z, Liu Z, Jia B, Wang F. PET Imaging of Neovascularization with (68)Ga-3PRGD₂ for Assessing Tumor Early Response to Endostar Antiangiogenic Therapy. Mol Pharm. 2014 Nov 3;11(11):3915-22.

12. Wu M^#, Shi J^#, Fan D, Zhou Q, Wang F, Niu Z, Huang Y. Biobehavior in normal and tumor-bearing mice of tobacco mosaic virus. Biomacromolecules. 2013 Nov 11;14(11):4032-7.

13. Luo H^#, Shi J^#, Jin H^#, Fan D, Lu L, Wang F*, Zhang Z*. An (125)I-labeled octavalent peptide fluorescent nanoprobe for tumor-homing imaging in vivo. Biomaterials. 2012 Jun;33(19):4843-50.

14. Shi J, Zhou Y, Chakraborty S, Kim YS, Jia B, Wang F, Liu S. Evaluation of ¹¹¹In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics. 2011;1:322-40.

15. Shi J^#, Liu TW^#, Chen J, Green D, Jaffray D, Wilson BC, Wang F, Zheng G. Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer. Theranostics. 2011;1:363-70.

16. Liu Z^#, Shi J^#, Jia B, Yu Z, Liu Y, Zhao H, Li F, Tian J, Chen X, Liu S, Wang F. Two (90)Y-Labeled Multimeric RGD Peptides RGD₄ and 3PRGD₂ for Integrin Targeted Radionuclide Therapy. Mol Pharm. 2011, 8(2):591-599.

17. Shi J, Wang L, Kim YS, Zhai S, Jia B, Wang F, Liu S. ^99mTcO(MAG₂-3G₃-dimer): a new integrin α_vβ₃-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging. 2009, 36(11):1874-1884.

18. Shi J, Kim YS, Chakraborty S, Jia B, Wang F, Liu S. 2-Mercaptoacetylglycylglycyl (MAG2) as a Bifunctional Chelator for ^99mTc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics. Bioconjug Chem. 2009, 20(8):1559-1568.

19. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S. Improving tumor uptake and pharmacokinetics of ⁶⁴Cu-labeled cyclic RGD peptide dimers with Gly₃ and PEG₄ linkers. Bioconjug Chem. 2009, 20(4):750-759.　

20. Shi J, Wang L, Kim YS, Zhai S, Liu Z, Chen X, Liu S.Improving tumor uptake and excretion kinetics of ^99mTc-labeled cyclic arginine-glycine -aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008, 51(24):7980-7990.